Jump to content

Narnatumab

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by DMacks (talk | contribs) at 22:45, 22 June 2020 (Remove malformatted |molecular_weight= when infobox can autocalculate it, per Wikipedia talk:WikiProject Pharmacology#Molecular weights in drugboxes (via WP:JWB)). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Narnatumab
Monoclonal antibody
TypeWhole antibody
SourceMouse
TargetMST1R (aka RON)
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6454H10026N1754O2020S44
Molar mass145922.10 g·mol−1
 ☒NcheckY (what is this?)  (verify)

Narnatumab is a human monoclonal antibody designed for the treatment of cancer.[1] Clinical development was abandoned after phase I trials.[2]

Narnatumab was developed by ImClone Systems.

References

  1. ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Narnatumab" (PDF). American Medical Association.
  2. ^ "Narnatumumab". AdisInsight. Retrieved 31 January 2017.